If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
449.20    1.50 (0.34%)
Bid:
445.90
Ask:
446.00
Spread: 0.10 (0.022%)
Market Cap: £11.30b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Directorate Change

25 Nov 2024 07:00

RNS Number : 4179N
Rentokil Initial PLC
25 November 2024
 

 

Directorate Change: Rentokil Initial plc appoints Paul Edgecliffe-Johnson as new Chief Financial Officer. Current CFO Stuart Ingall-Tombs to retire.

 

Rentokil Initial plc (FTSE: RTO, "the Company") today announces that Paul Edgecliffe-Johnson will join the Board as Chief Financial Officer on 1 January 2025, succeeding Stuart Ingall-Tombs, who is retiring and will step down from the Board on 31 December 2024 after 17 years with the Company, most recently as Chief Financial Officer for 4 years.

 

Paul Edgecliffe-Johnson brings 25 years' experience in finance and international businesses, having most recently been CFO and a member of the Board at Flutter Entertainment PLC. Prior to that he was CFO, Group Head of Strategy, and member of the Board and Executive Committee at InterContinental Hotels Group PLC ("IHG"). Before joining IHG in 2004, Paul was an Associate Director, Corporate Finance at HSBC Holdings PLC.

 

Paul will join the Company on 1 December 2024 as CFO Designate as part of the transition process. Following 1 January 2025, Stuart will continue to be available to support a smooth handover to Paul, including assisting with the completion of the Company's financial statements for the year ending 31 December 2024.

 

Richard Solomons, Chair, said:

 

"We are delighted to announce the appointment of Paul as the Company's new Chief Financial Officer. After a robust selection process, we are confident that he possesses the right skills and experience needed to lead our financial operations and deliver business success. He is a seasoned financial executive with over a decade of company CFO experience, including at IHG where we worked together. Paul has a proven track record of driving profitable growth, optimising financial performance and implementing strategic initiatives.

 

"On behalf of the Board, I would like to thank Stuart for his contributions to Rentokil Initial over many years of committed service and to wish him a happy and healthy retirement."

 

Andy Ransom, Chief Executive, said:

 

"I would like to thank Stuart for his unwavering commitment to Rentokil Initial over the 17 years he has been with the Company. I wish him all the best and hope he has a wonderful time in his retirement.

 

"I am delighted that we have appointed Paul as Chief Financial Officer. He has an exceptional track record and reputation, and I am confident he will make a significant impact in this critical role. I am really looking forward to us working together, as his breadth of experience, along with the insights and guidance he will bring, will be invaluable as we continue to execute our Right Way Strategy in North America and across the rest of the Group."

 

Paul Edgecliffe-Johnson said:

 

"I am excited to join the talented team at Rentokil Initial and to contribute to the growth journey of this global leader. I look forward to leveraging my experience, while maintaining a strong focus on operational excellence, financial discipline and value creation."

 

 

 

Notes:

 

1. Stuart Ingall-Tombs will be treated as a good leaver by reason of his retirement for the purposes of annual bonus and awards under the Deferred Bonus Plan and Performance Share Plan in accordance with the Company's Directors' Remuneration Policy and the relevant plan rules. Further details will be disclosed on the Company's website in due course in compliance with Section 430(2B) of the Companies Act 2006, and details will also be disclosed in the Directors' Remuneration Report within the Company's Annual Report and Accounts for the year ending 31 December 2024.

2. There are no further details to be disclosed relating to Paul Edgecliffe-Johnson under Listing Rule 6.4.8.

 

 

Enquiries:

 

Investors / Analysts: Peter Russell, Rentokil Initial plc: + 44(0)7795166506

Media: Malcolm Padley, Rentokil Initial plc: +44(0)7788978199

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPGRUGUPCGUC
Date   Source Headline
29th Aug 20187:00 amRNSDirector/PDMR Shareholding
20th Aug 201812:44 pmRNSDirector/PDMR Shareholding
1st Aug 20183:12 pmRNSHolding(s) in Company
31st Jul 20187:00 amRNSInterim Results
27th Jul 20185:07 pmRNSHolding(s) in Company
5th Jul 20184:52 pmRNSHolding(s) in Company
5th Jul 201811:36 amRNSDirector Declaration
28th Jun 20184:10 pmRNSHolding(s) in Company
7th Jun 20185:16 pmRNSDirector Declaration
17th May 20184:12 pmRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSNotice of Capital Markets Days
9th May 20185:40 pmRNSResult of AGM
4th May 20184:27 pmRNSDirector/PDMR Shareholding
2nd May 201810:52 amRNSDirector/PDMR Shareholding
1st May 20186:00 pmRNSDirector/PDMR Shareholding
30th Apr 20185:48 pmRNSDirector/PDMR Shareholding
26th Apr 20183:24 pmRNSHolding(s) in Company
25th Apr 20184:50 pmRNSHolding(s) in Company
24th Apr 20183:55 pmRNSHolding(s) in Company
24th Apr 201810:53 amRNSHolding(s) in Company
20th Apr 20184:09 pmRNSDirector/PDMR Shareholding
19th Apr 20184:32 pmRNSHolding(s) in Company
19th Apr 20187:00 amRNSQ1 Trading Update
5th Apr 201812:57 pmRNSHolding(s) in Company
5th Apr 201811:06 amRNSAnnual Financial Report
4th Apr 20186:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20184:12 pmRNSBlock listing Interim Review
29th Mar 201811:55 amRNSTotal Voting Rights
27th Mar 20184:01 pmRNSHolding(s) in Company
27th Mar 201812:58 pmRNSAdditional Listing
8th Mar 20185:50 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSFinal Results
27th Dec 20177:00 amRNSDirector/PDMR Shareholding
20th Dec 20173:40 pmRNSDirector/PDMR Shareholding
22nd Nov 20174:30 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSIssue of new EUR400m bond
13th Nov 20174:35 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSPurchase of Vector Disease Acquisition LLC
7th Nov 20174:14 pmRNSHolding(s) in Company
6th Nov 20177:00 amRNSDirectorate Change
2nd Nov 20176:07 pmRNSHolding(s) in Company
1st Nov 20177:00 amRNSDirectorate Change
19th Oct 20177:00 amRNSQ3 Trading Update
2nd Oct 20173:26 pmRNSBlock listing Interim Review
21st Sep 20177:00 amRNSDirectorate Change
18th Sep 20177:00 amRNSDirectorate Change
22nd Aug 20173:34 pmRNSChange to Director's details
4th Aug 201711:57 amRNSDirector/PDMR Shareholding
31st Jul 20172:16 pmRNSDirector Declaration
27th Jul 20177:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.